Iralukast

Cat. No.:	HY-101944
CAS No.:	151581-24-7
Molecular Formula:	$C_{38}H_{37}F_3O_8S$
Molecular Weight:	710.76
Target:	Leukotriene Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the COA.



BIOLOGICAL ACTIVITY

Description	Iralukast is a cysteinyl-leukotriene antagonist (**CysLT**) with a pK_i of 7.8 for **$CysLT_1$**.
IC_{50} & Target	$CysLT_1$ 7.8 (pKi)
In Vitro	Both Iralukast and CGP 57698 are able to compete for the two sites labelled by [^{3}H]-LTD4. As in all the G-protein coupled receptors, Iralukast and CGP 57698 do not discriminate between the high and the low affinitystates of the CysLT receptor labelled by LTD_4 (K_{i1}=K_{i2}=16.6 nM±36% CV and K_{i1}=K_{i2}=5.7 nM±19% CV, respectively). Iralukast, displays a slow bindingkinetic, because preincubation (15 min) increases its antagonist potency. Iralukast and CGP 57698 antagonize LTD_4-induced contraction of humanbronchi, with pA_2 values of 7.77±4.3% CV and 8.51±1.6% CV, respectively, and slopes not significantly different from unity[2].

REFERENCES

[1]. Magnus Bäck, et al. Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. Br J Pharmacol. 2014 Aug; 171(15): 3551–3574.

[2]. Valérie Capra, et al. Pharmacological characterization of the cysteinyl-leukotrieneantagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro.Br J Pharmacol. 1998 Feb; 123(3): 590–598.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA